- Vetter was named CDMO of the Year in the “Finished Dose” category at the 2026 CDMO Leadership Awards during DCAT Week in New York.
- The recognition reflects sponsor feedback and highlights the company’s role in injectable drug development and contract manufacturing.
Vetter has been named CDMO of the Year in the “Finished Dose” category at the 2026 CDMO Leadership Awards, presented during DCAT Week in New York on March 25. The award recognizes contract manufacturing organizations based on sponsor feedback and independent research evaluating performance and capabilities.
The recognition highlights Vetter’s role as a CDMO supporting injectable drug development and manufacturing from early clinical phases through regulatory approval and commercial supply. The company stated that it continues to invest in technologies, capacity, and quality systems to address increasing complexity in biologics and related handling processes.
Vetter also outlined ongoing expansion efforts across Europe and the United States, including approximately €2 billion in planned capacity investments through 2035. These initiatives are intended to strengthen its global manufacturing footprint and support long-term supply capabilities for pharmaceutical partners.
The CDMO Leadership Awards are determined through independent research conducted by the Tufts Center for the Study of Drug Development, using sponsor evaluations and outsourcing performance data. The program recognizes companies across multiple categories, including biologics, cell and gene therapy, small molecule APIs, finished dose, and fill-finish services.
“We are committed to supporting our customers every day, and this award recognizes our ongoing efforts to provide the best customer service experience possible.”
Lars Hahn, Senior Vice President Global Sales Organization at Vetter
